Literature DB >> 3463546

Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization.

H Petri, H Tronnier.   

Abstract

Thirty-four patients suffering from various skin infections caused by gram-positive and gram-negative pathogens were treated with enoxacin (400 to 800 mg/day) for 8 to 14 days. A marked abatement of clinical symptoms, accompanied by eradication of the causative pathogens was observed in all 34 patients. Enoxacin was well tolerated. The minimal erythema dose of UVA light was reduced by a mean of 45% in three of the twenty patients receiving the 800 mg daily dosage of enoxacin. No positive reactions could be provoked in a subsequently applied photopatch test, allergic reactions were not observed. These mild reactions seen in a small percentage of patients appear to indicate further specific tests to determine a possible photosensitization effect of enoxacin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463546     DOI: 10.1007/BF01667847

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  4 in total

1.  Phototoxic reactions from some common drugs provoked by a high-intensity UVA lamp.

Authors:  K Rosén; G Swanbeck
Journal:  Acta Derm Venereol       Date:  1982       Impact factor: 4.437

2.  A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea.

Authors:  A Notowicz; E Stolz; B van Klingeren
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

3.  Identification of systemic phototoxic drugs by human intradermal assay.

Authors:  K H Kaidbey; A M Kligman
Journal:  J Invest Dermatol       Date:  1978-05       Impact factor: 8.551

4.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

  4 in total
  3 in total

Review 1.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 2.  Clinical features and management of adverse effects of quinolone antibacterials.

Authors:  J H Paton; D S Reeves
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 3.  Review of tissue penetration and clinical efficacy of enoxacin in skin and skin structure infections and in osteomyelitis.

Authors:  G A Pankey
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.